Figure 2.

Phase II trials: SVR rate with DAA in HCVG1 non responders. Blue, Triple combo with PI + PR. Yellow, QUAD with P+R. Green, interferon free combos.

Puoti et al. BMC Infectious Diseases 2012 12(Suppl 2):S7   doi:10.1186/1471-2334-12-S2-S7